Utah Medical Products, Inc.
NASDAQ:UTMDMedical - Instruments & Supplies
+$1.10 today
- Market cap
- $205.81M
- Beta
- 0.37
- P/E (TTM)
- 19.6
- EPS (TTM)
- $3.41
- Dividend yield
- 1.85%
Volume 0.02M
Average 0.01M
UTMD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Utah Medical Products, Inc.NASDAQ: UTMD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $2.6M fell 14.4% year over year, ahead of the -16.3% change in trailing-twelve-month net income. Sequentially, it rose 1.5% from the prior quarter. Over 3 fiscal years it compounded at -11.8% a year.
Context
- Net income amounted to 29.3% of revenue in FY2025, down 4.6 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -14.4% holds above the trailing-twelve-month pace of -16.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 11.29M USD
- Year-over-year change
- -18.7%
- 4-year CAGR
- -6.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.29M | -18.7% |
| FY2024 | 2024-12-31 | 13.87M | -16.6% |
| FY2023 | 2023-12-31 | 16.64M | +1.0% |
| FY2022 | 2022-12-31 | 16.47M | +11.4% |
| FY2021 | 2021-12-31 | 14.79M | — |
Net Income vs competitors
How UTMD compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -16.3% is the 9th highest of 11, against a peer median of +33.2%.
- Net income amounts to 28.9% of revenue for UTMD, versus a peer median of 60.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $465.5M USD | +369.3% | — | 992.9% | |
| LTM Mar 2026 | $111.13M USD | +30.5% | +91.6% | 17982.7% | |
| LTM Mar 2026 | €83.7M EUR | +24.9% | +44.2% | 512.9% | |
| LTM Mar 2026 | $71.83M USD | +124.8% | -84.4% | 63.6% | |
| LTM Mar 2026 | $65.41M USD | +35.9% | -34.8% | 57.5% | |
| LTM Mar 2026 | $39.2M USD | +21.2% | +14.1% | 207.7% | |
| LTM Mar 2026 | $37.52M USD | -22.7% | +1.7% | 24.7% | |
| LTM Mar 2026 | $21.94M USD | +461.3% | -23.8% | 28.7% | |
| LTM Mar 2026 | $10.85M USD | -16.3% | -11.8% | 28.9% | |
| LTM Mar 2026 | $7.91M USD | +148.0% | +616.7% | 5.6% | |
| LTM Mar 2026 | $2.28M USD | -57.0% | -32.7% | 5.3% | |
| Peer median (excluding UTMD) | — | +33.2% | +1.7% | 60.5% | |
Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 14.79M | 16.47M | 16.64M | 13.87M | 11.29M |
| Depreciation & Amortization | 7.28M | 7.08M | 6.37M | 2.85M | 3.01M |
| Deferred Income Tax | (92K) | (401K) | (681K) | (338K) | (659K) |
| Stock-Based Compensation | 166K | 183K | 225K | 256K | 373K |
| Change in Working Capital | (1.01M) | (2.23M) | (233K) | (1.8M) | 317K |
| Accounts Receivables | (1.13M) | (525K) | 2.27M | (781K) | 333K |
| Inventory | (485K) | (2.35M) | (670K) | 587K | 1.2M |
| Accounts Payables | (23K) | 464K | (456K) | (73K) | 211K |
| Other Working Capital | 632K | 188K | (1.38M) | (1.54M) | (1.42M) |
| Other Non-Cash Items | 63K | 36K | (33K) | (4K) | 367K |
| Operating Cash Flow | 21.2M | 21.15M | 22.28M | 14.83M | 14.69M |
| Capital Expenditures | (552K) | (818K) | (639K) | (235K) | (371K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (9K) | 0 | 27K | 0 |
| Investing Cash Flow | (552K) | (818K) | (639K) | (208K) | (371K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (2.5M) | 0 | (19.97M) | (8.36M) |
| Dividends Paid | (11.47M) | (3.16M) | (4.28M) | (4.26M) | (3.98M) |
| Other Financing Activities | 560K | 174K | 117K | 390K | 0 |
| Financing Cash Flow | (10.91M) | (5.48M) | (4.17M) | (23.84M) | (12.34M) |
| Effect of Forex Changes | (362K) | (767K) | 339K | (677K) | 797K |
| Net Change in Cash | 9.38M | 14.08M | 17.82M | (9.89M) | 2.78M |
| Free Cash Flow | 20.65M | 20.33M | 21.64M | 14.6M | 14.32M |
Utah Medical Products, Inc.
NASDAQ:UTMD
Intrinsic Alpha fair value
Locked
Current Price
$72.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.